Healthsens is currently developing the only immunological POCT (Point of Care Testing) device that will allow the early and non-invasive diagnosis of prostate cancer. Healthsens Prostasens is a biotechnological innovation that will be able to calculate the prostate health index (PHI), which will allow patients to control their disease, changing the lives of millions of people. 

Healthsens is developing a low-cost, portable point-of-care testing (POCT) device that will quantify three biomarkers associated with prostate cancer in a single drop of serum. The final measuring device shall be an electrochemical sensor, consisting of three electrodes, which shall allow the simultaneous determination and with a high degree of accuracy of total PSA, free PSA and [-2]proPSA.

Unlike the methods commonly used in clinical practice, Healthsens Prostasens^® will allow, in a simple and non-invasive way, to obtain comprehensive information on the probability of developing prostate cancer in patients, not only provide an isolated concentration value, but also calculate the prostate health index (PHI).

PHI, calculated from total serum PSA concentration, free PSA, and [-2]proPSA, is a multivariate index that indicates the presence of a tumor and its stage of development, as well as degree of aggressiveness. The use of PHI is approved in Europe, USA (FDA) and Australia.

The commercialization of the Healthsens Prostasens^® device aims to facilitate the early diagnosis of prostate cancer, so that it is accessible to patients.  Healthsens Prostasens‍ will allow to carry out population screening quickly and easily, without the need for rectal examinations or biopsies, and all at a very low cost.